Claims for Patent: 8,808,700

Summary for Patent: 8,808,700

Title:	Use of TNF alpha inhibitor for treatment of erosive polyarthritis
Abstract:	The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s):	Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Glenview, IL)
Assignee:	AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:	14/228,791
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,808,700
Patent Claims:	1. A method for treating erosive polyarthritis, comprising administering a human anti-TNF.alpha. antibody to a human subject having erosive polyarthritis associated with psoriatic arthritis, ankylosing spondylitis or juvenile rheumatoid arthritis, wherein a modified Total Sharp Score (mTSS) of the subject is maintained or decreased following said treating as compared to baseline prior to said treating, and wherein the human anti-TNF.alpha. antibody comprises (1) a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and (2) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 2. The method of claim 1, wherein the human subject has erosive polyarthritis associated with psoriatic arthritis. 3. The method of claim 1, wherein the human subject has erosive polyarthritis associated with ankylosing spondylitis. 4. The method of claim 2, wherein the change between baseline mTSS of the subject prior to said treating, and mTSS of the subject following said treating, is -0.2. 5. The method of claim 3, wherein the change between baseline mTSS of the subject prior to said treating, and mTSS of the subject following said treating, is -0.2. 6. The method of claim 1, wherein said anti-TNF.alpha. antibody is adalimumab. 7. The method of claim 6, wherein said adalimumab is administered to the human subject subcutaneously at a dose of 40 mg on a biweekly dosing regimen. 8. The method of claim 7, wherein the human subject has erosive polyarthritis associated with psoriatic arthritis. 9. The method of claim 7, wherein the human subject has erosive polyarthritis associated with ankylosing spondylitis. 10. The method of claim 7, wherein the change between baseline mTSS of the subject prior to said treating, and mTSS of the subject following said treating, is -0.2. 11. The method of claim 8, wherein the change between baseline mTSS of the subject prior to said treating, and mTSS of the subject following said treating, is -0.2. 12. The method of claim 9, wherein the change between baseline mTSS of the subject prior to said treating, and mTSS of the subject following said treating, is -0.2. 13. The method of claim 8, wherein said treating lasts 24 weeks. 14. The method of claim 8, wherein the human subject achieves PASI75 response following said treating. 15. The method of claim 8, wherein the human subject achieves PASI90 response following said treating. 16. The method of claim 8, wherein the human subject achieves ACR50 response following said treating. 17. The method of claim 8, wherein the human subject achieves ACR70 response following said treating. 18. The method of claim 9, wherein the human subject achieves ACR50 response following said treating. 19. The method of claim 9, wherein the human subject achieves ACR70 response following said treating. 20. A method for treating TNF.alpha.-related disorders capable of causing erosive polyarthritis, comprising administering a human anti-TNF.alpha. antibody to a human subject having erosive polyarthritis associated with psoriatic arthritis, ankylosing spondylitis or juvenile rheumatoid arthritis, such that radiographic progression in the human subject is inhibited, wherein the human anti-TNF.alpha. antibody comprises (1) a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and (2) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 21. The method of claim 20, wherein the human subject has erosive polyarthritis associated with psoriatic arthritis. 22. The method of claim 20, wherein the human subject has erosive polyarthritis associated with ankylosing spondylitis. 23. The method of claim 20, wherein said anti-TNF.alpha. antibody is adalimumab. 24. The method of claim 23, wherein said adalimumab is administered to the human subject subcutaneously at a dose of 40 mg on a biweekly dosing regimen. 25. The method of claim 24, wherein the human subject has erosive polyarthritis associated with psoriatic arthritis. 26. The method of claim 24, wherein the human subject has erosive polyarthritis associated with ankylosing spondylitis. 27. The method of claim 25, wherein the human subject achieves PASI75 response following said treating. 28. The method of claim 26, wherein the human subject achieves ACR50 response following said treating. 29. A method for treating structural damage associated with psoriatic arthritis, comprising administering adalimumab subcutaneously at a dose of 40 mg every other week to a human subject having structural damage associated with psoriatic arthritis, such that progression of structural damage in the human subject is inhibited or lessened. 30. The method of claim 29, wherein the change between baseline mTSS of the subject prior to said treating, and mTSS of the subject following said treating, is -0.2.

Details for Patent 8,808,700

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2021-03-07